JPMorgan Chase & Co. Reduces Holdings in Cellebrite DI Ltd. $CLBT

JPMorgan Chase & Co. decreased its position in shares of Cellebrite DI Ltd. (NASDAQ:CLBT) by 21.2% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 683,842 shares of the company’s stock after selling 183,531 shares during the period. JPMorgan Chase & Co. owned approximately 0.29% of Cellebrite DI worth $12,672,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the company. Venturi Wealth Management LLC grew its holdings in Cellebrite DI by 5.0% during the 3rd quarter. Venturi Wealth Management LLC now owns 14,700 shares of the company’s stock valued at $272,000 after purchasing an additional 700 shares during the last quarter. CWM LLC grew its stake in shares of Cellebrite DI by 85.7% during the third quarter. CWM LLC now owns 1,560 shares of the company’s stock valued at $29,000 after buying an additional 720 shares during the last quarter. Blue Trust Inc. raised its holdings in shares of Cellebrite DI by 4.0% in the third quarter. Blue Trust Inc. now owns 23,121 shares of the company’s stock worth $428,000 after buying an additional 898 shares during the period. SkyView Investment Advisors LLC raised its holdings in shares of Cellebrite DI by 2.6% in the second quarter. SkyView Investment Advisors LLC now owns 37,708 shares of the company’s stock worth $597,000 after buying an additional 970 shares during the period. Finally, Fox Run Management L.L.C. lifted its stake in shares of Cellebrite DI by 3.9% during the 2nd quarter. Fox Run Management L.L.C. now owns 30,359 shares of the company’s stock worth $486,000 after acquiring an additional 1,127 shares during the last quarter. Institutional investors own 45.88% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on CLBT shares. Needham & Company LLC reduced their target price on Cellebrite DI from $24.00 to $18.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Bank of America raised their price target on shares of Cellebrite DI from $24.00 to $25.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Wall Street Zen lowered shares of Cellebrite DI from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Lake Street Capital upped their target price on shares of Cellebrite DI from $22.00 to $23.00 and gave the stock a “buy” rating in a research note on Thursday, November 13th. Finally, JPMorgan Chase & Co. raised their target price on shares of Cellebrite DI from $23.00 to $24.00 and gave the stock an “overweight” rating in a research report on Thursday, November 13th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $22.50.

Cellebrite DI Stock Up 7.3%

Shares of CLBT stock opened at $15.19 on Friday. The firm has a market cap of $3.79 billion, a price-to-earnings ratio of 49.00, a PEG ratio of 2.17 and a beta of 1.30. Cellebrite DI Ltd. has a 52-week low of $11.76 and a 52-week high of $20.86. The company’s 50 day moving average is $15.67 and its 200 day moving average is $16.95.

Cellebrite DI (NASDAQ:CLBT) last announced its earnings results on Wednesday, February 11th. The company reported $0.14 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.14. Cellebrite DI had a return on equity of 20.43% and a net margin of 16.47%.The business had revenue of $128.82 million for the quarter, compared to analysts’ expectations of $126.07 million. During the same quarter last year, the firm earned $0.10 EPS. The business’s revenue for the quarter was up 28.8% on a year-over-year basis. Analysts anticipate that Cellebrite DI Ltd. will post 0.3 EPS for the current fiscal year.

Cellebrite DI Profile

Cellebrite DI is a global provider of digital intelligence and forensics solutions that enable law enforcement agencies, government bodies and enterprises to extract, analyze and act on data from mobile devices, cloud services and digital sources. The company’s technology is designed to accelerate investigations, support evidence-based decision-making and enhance security operations by delivering actionable intelligence in a secure, scalable platform.

The company’s flagship offerings include the Universal Forensic Extraction Device (UFED) series for data acquisition and decoding, Physical Analyzer for advanced data parsing and visualization, and Pathfinder for case-driven investigation workflows.